Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 326 - 350 of 14508 in total

Carglumic acid

Carglumic acid is a drug used for the treatment of hyperammonemia in patients with a deficiency in N-acetyl glutamate synthase. This rare genetic disorder results in elevated blood levels of ammonia, which can eventually cross the blood–brain barrier and cause neurologic problems, cerebral edema, coma, and death. Carglumic acid was...
Approved
Matched Description: … Food and Drug Administration (FDA) on 18 March 2010. ... cause neurologic problems, cerebral edema, coma, and death. ... disorder results in elevated blood levels of ammonia, which can eventually cross the blood–brain barrier and …
Matched Categories: … Amino Acids and Derivatives ... Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins …

Iothalamic acid

Iothalamic acid is an iodine containing organic anion used as a diagnostic contrast agent.
Approved

Technetium Tc-99m tetrofosmin

Technetium Tc-99m tetrofosmin is a drug used in nuclear myocardial perfusion imaging. The radioisotope, technetium-99m, is chelated by two 1,2-bis[di-(2-ethoxyethyl)phosphino]ethane ligands which belong to the group of diphosphines and which are referred to as tetrofosmin. It is a lipophilic technetium phosphine dioxo cation that was formulated into a freeze-dried kit...
Approved
Matched Description: … by two 1,2-bis[di-(2-ethoxyethyl)phosphino]ethane ligands which belong to the group of diphosphines and ... [A31592] Technetium Tc-99m tetrofosmin was developed by GE Healthcare and FDA approved on February 9, …
Matched Categories: … Indicators and Reagents …

Levamlodipine

Levamlodipine, also known as S-amlodipine, is a pharmacologically active enantiomer of amlodipine, an antihypertensive medication. Levamlodipine belongs to the dihydropyridine group of calcium channel blockers. This medication was first marketed in Russia and India before being granted FDA approval. The names S-amlodipine and levamlodipine may be used interchangeably as both...
Approved
Investigational
Matched Description: … [L10833] This medication was first marketed in Russia and India before being granted FDA approval. ... [L1484] The names S-amlodipine and levamlodipine may be used interchangeably as both substances are the ... [L10833] As a racemic mixture, amlodipine contains (R) and (S)-amlodipine isomers, but only (S)-amlodipine …

Strontium ranelate

Strontium ranelate, a strontium (II) salt of ranelic acid, is a medication for osteoporosis. Some reports have shown that strontium ranelate can slow down the progression of osteoarthritis of the knee. This agent presents an atypical mechanism of action in which it increases deposition of new bone by osteoblasts and,...
Approved
Withdrawn
Matched Description: … intrinsic bone tissue quality and microarchitecture in osteoporosis by way of a number of cellular and ... presents an atypical mechanism of action in which it increases deposition of new bone by osteoblasts and ... increased adverse cardiac effects profile along with increased risk of venous thromboembolism (VTE) and …
Matched Categories: … strontium ranelate and colecalciferol ... Drugs Affecting Bone Structure and Mineralization …

Ioxaglic acid

Ioxaglic acid is marketed as Hexabrix. This drug is an ionic tri-iodinated benzoate used as a low-osmolality contrast agent during diagnostic imaging procedures. Like other organic iodine compounds, ioxaglic acid blocks x-rays and is opaque in its appearance on x-ray film, improving the visualization of important structures and organs during...
Approved
Investigational
Matched Description: … , arthrography, cholangiography, urography, and computed tomography [L1889]. ... Like other organic iodine compounds, ioxaglic acid blocks x-rays and is opaque in its appearance on x-ray ... film, improving the visualization of important structures and organs during angiography, arteriography …

Metrizoic acid

Metrizoic acid is a molecule used as a contrast medium. It present a higher risk of allergic reactions due to its high osmolality. Its approval has been discontinued by the FDA. One study in 1976 demonstrated that metrizoic acid, when used for cardiac angiography, was well tolerated. A total of...
Approved
Matched Description: … Seven cases of ventricular fibrillation, and 5 of significant bradycardia/asystole, were associated with …

Tetrofosmin

Tetrofosmin was developed to overcome the non-target uptake of radioligands by the generation of hetero-atomic compounds. It presents a molecular formula of 1,2-bis(bis(2-ethoxyethyl)phosphino)ethane. Tetrofosmin is part of the group of diphosphines. Tetrofosmin is used in conjunction with technetium Tc-99m as a radiopharmaceutical.
Approved

Oftasceine

Oftasceine is also referred to as Fluorexon. It is used in ophthalmic solutions as a staining agent when fitting soft and hard lenses. It is a fluorescent dye or luminescent agent.
Approved
Matched Description: … It is used in ophthalmic solutions as a staining agent when fitting soft and hard lenses. …

Pentoxyverine

Pentoxyverine, also referred to as carbetapentane, is a non-opioid central acting antitussive with antimuscarinic, anticonvulsant , and local anesthetic properties. It is an active ingredient in over-the-counter cough suppressants in combination with guaifenesin and H1-receptor antagonists . Pentoxyverine acts on sigma-1 receptors, as well as kappa and mu-opioid receptors. The...
Approved
Investigational
Withdrawn
Matched Description: … Pentoxyverine acts on sigma-1 receptors, as well as kappa and mu-opioid receptors. ... It is an active ingredient in over-the-counter cough suppressants in combination with guaifenesin and ... carbetapentane, is a non-opioid central acting antitussive with antimuscarinic, anticonvulsant [A32717], and …
Matched Categories: … Cough and Cold Preparations …

Ethyl ferulate

Approved
Experimental

Latanoprostene bunod

Latanoprostene Bunod has been used in trials studying the treatment of Glaucoma, Ocular Hypertension, Open-Angle Glaucoma, Open Angle Glaucoma, and Intraocular Pressure. As of November 2, 2017 the FDA approved Bausch + Lomb's Vyzulta (latanoprostene bunod opthalmic solution), 0.024% for the indication of reducing intraocular pressure in patients with open-angle...
Approved
Investigational
Matched Description: … studying the treatment of Glaucoma, Ocular Hypertension, Open-Angle Glaucoma, Open Angle Glaucoma, and ... In comparison, both latanoprost and latanoprostene bunod contain a latanoprost acid backbone. ... mechanism of action that stems from both its prostaglandin F2-alpha analog latanoprost acid metabolite and …
Matched Categories: … Antiglaucoma Preparations and Miotics …

Tropisetron

Tropisetron is an indole derivative with antiemetic activity. As a selective serotonin receptor antagonist, tropisetron competitively blocks the action of serotonin at 5HT3 receptors, resulting in suppression of chemotherapy- and radiotherapy-induced nausea and vomiting. Tropisetron appears to be well tolerated with the most frequently reported adverse effect being headache. Extrapyramidal...
Approved
Investigational
Matched Description: … radiotherapy-induced nausea and vomiting. ... competitively blocks the action of serotonin at 5HT3 receptors, resulting in suppression of chemotherapy- and …
Matched Categories: … Alimentary Tract and Metabolism ... Antiemetics and Antinauseants …

Cabotegravir

Cabotegravir, or GSK1265744, is an HIV-1 integrase inhibitor that is prescribed with the non-nucleoside reverse transcriptase inhibitor, rilpivirine.[A227668,L31188,L31193] Early research into cabotegravir showed it had lower oral bioavailability than dolutegravir, which resulted in the development of long acting monthly intramuscular injection formulation for cabotegravir.[A227668,L31193] Cabotegravir was granted FDA approval on...
Approved
Investigational
Matched Description: … combination product was granted FDA approval for dosing every two months on February 01, 2022 [L40084] and …

Bictegravir

Bictegravir is a recently approved investigational drug that has been used in trials studying the treatment of HIV-1 and HIV-2 infection. It has been approved for HIV-1 monotherapy combined with 2 other antiretrovirals in a single tablet.
Approved
Investigational
Matched Description: … recently approved investigational drug that has been used in trials studying the treatment of HIV-1 and …
Matched Categories: … emtricitabine, tenofovir alafenamide and bictegravir …

Hexobendine

Hexobendine is a medication used to cause vasodilation, to treat several conditions including angina pectoris. It has not been approved in the United States or the United Kingdom, but has been used widely in Austria and Germany .
Approved
Matched Description: … has not been approved in the United States or the United Kingdom, but has been used widely in Austria and …

Ritiometan

Ritiometan is a nasal spray which is marketed by the name Nécyrane in France. It is indicated for use in viral rhinitis/ the common cold.
Approved

p-Phenylenediamine

Approved
Experimental
Matched Categories: … Indicators and Reagents ... Amino Acids, Peptides, and Proteins …

Lithium citrate

Approved

Agalsidase beta

Agalsidase beta is a recombinant human α-galactosidase A similar to agalsidase alfa. While patients generally do not experience a clinically significant difference in outcomes between the two drugs, some patients may experience greater benefit with agalsidase beta.[A220228,A220233] Use of agalsidase beta has decreased in Europe, in favor of agalsidase alfa,...
Approved
Investigational
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins …

Velaglucerase alfa

Velaglucerase alfa is a gene-activated human recombinant glucocerebrosidase used for the treatment of Type 1 Gaucher disease, caused by a deficiency of the lysosomal enzyme glucocerebrosidase. Additionally, Velaglucerase alfa has also been investigated for use in Type 3 Gaucher disease.
Approved
Investigational
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism …

Eflornithine

Eflornithine is an irreversible ornithine decarboxylase inhibitor originally developed as a treatment for human African trypanosomiasis. Further research has also implicated ornithine decarboxylase in other conditions like facial hirsutism and cancer, especially when ornithine decarboxylase is highly upregulated in tumor cells.[A4112, A262834] Additionally, ornithine decarboxylase is activated by c-myc or...
Approved
Withdrawn
Matched Description: … [A262839] In 1960 and 2000, the FDA approved eflornithine under the brand names ORNIDYL and VANIQUA ... Further research has also implicated ornithine decarboxylase in other conditions like facial hirsutism and ... under the brand name IWILFIN as an oral maintenance therapy to reduce the risk of relapse in adult and …
Matched Categories: … Skin and Mucous Membrane Agents ... Amino Acids, Peptides, and Proteins ... Agents Against Leishmaniasis and Trypanosomiasis ... Antineoplastic and Immunomodulating Agents ... Antiparasitic Products, Insecticides and Repellents …

Oxyquinoline

Oxyquinoline is a heterocyclic phenol and derivative of quinoline with antiseptic, disinfectant, and pesticide properties. It is used as a stabilizer for hydrogen peroxide, where it is sometimes added in cosmetic products.
Approved
Vet approved
Matched Description: … Oxyquinoline is a heterocyclic phenol and derivative of quinoline with antiseptic, disinfectant, and …
Matched Categories: … Alimentary Tract and Metabolism ... Antiseptics and Disinfectants ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics ... Antiinfectives and Antiseptics for Local Oral Treatment …

Artesunate

Artesunate is indicated for the initial treatment of severe malaria. The World Health Organization recommends artesunate as first line treatment for severe malaria. Artesunate was developed out of a need for a more hydrophilic derivative of artemisinin. Artesunate was granted FDA approval on 26 May 2020.
Approved
Investigational
Matched Categories: … Artemisinin and derivatives ... artesunate and mefloquine ... artesunate and amodiaquine ... artesunate and pyronaridine ... artesunate, sulfalene and pyrimethamine …

Beremagene geperpavec

Beremagene geperpavec is a live, replication-defective herpes simplex virus type 1 (HSV-1)-based vector therapy. Developed by Krystal Biotech, it was first approved by the FDA on May 19, 2023, for the treatment of wounds associated with dystrophic epidermolysis bullosa (DEB). DEB is caused by mutations in the COL7A1 gene that...
Approved
Matched Categories: … Cellular and Gene Therapy ... Preparations for Treatment of Wounds and Ulcers …
Displaying drugs 326 - 350 of 14508 in total